Drug Profile


Alternative Names: CRx-197; CRx-197 high dose topical cream (0.1% nortriptyline HCl +0.3% loratadine); CRx-197 low dose topical cream (0.1% nortriptyline HCl + 0.1% loratadine); Nortriptyline/loratadine - Zalicus

Latest Information Update: 29 Mar 2011

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator CombinatoRx
  • Developer Zalicus
  • Class Anti-inflammatories; Antiallergics; Dibenzocycloheptenes; Piperidines; Skin disorder therapies; Tricyclic antidepressants
  • Mechanism of Action Cytokine modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Plaque psoriasis

Most Recent Events

  • 31 Dec 2010 Discontinued - Phase-II for Plaque psoriasis in Germany (Topical)
  • 09 Sep 2010 CombinatoRx is now called Zalicus
  • 14 Jan 2009 CombinatoRx completes a phase II trial for Plaque psoriasis in Germany (NCT00796211)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top